Gao Tong, Xu Wen, Li Xiao, Guo Qie, Liu Donghua, Zhang Xiaolei, Leng Ping, Sun Jialin
Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, China.
Front Pharmacol. 2025 Aug 18;16:1632568. doi: 10.3389/fphar.2025.1632568. eCollection 2025.
Immunosuppressive therapy remains the primary method for preventing rejection in renal transplant recipients. While multiple population pharmacokinetic (popPK) models of mycophenolate sodium (MPS) have been developed for this population, their predictive performance across different clinical settings remains unverified. This study systematically evaluated published MPS popPK models through external validation to assess their extrapolation potential.
Published MPS popPK models for renal transplant recipients were identified through systematic searches of PubMed, Embase and Web of Science. These models were externally evaluated using a cohort of renal transplant patients receiving MPS therapy at the Affiliated Hospital of Qingdao University. Model prediction performance was evaluated using three metrics: the goodness-of-fit method based on model prediction, prediction error test method and visual predictive checks method based on model simulation.
A total of 186 drug concentration data of 31 patients in our hospital were collected, and 4 literature were retrieved, among which 1 were one-compartment models and 3 were two-compartment models. In the goodness-of-fit diagnosis and prediction error test based on model prediction, the population prediction data of all models were not good, while the individual prediction data showed that the fitting result of Model 1 was relatively better. The visual prediction test results based on model simulation show that the fitting result of Model 1 was relatively good, while the distribution deviation between the observed data and the simulation data of the remaining models was large, and the fitting effect was not good.
The published models exhibit significant variability and unsatisfactory predictive performance, indicating that therapeutic drug monitoring (TDM) remains an essential requirement for the clinical application of MPS. To advance individualized medication for MPS based on popPK, future research must prioritize the investigation of potential covariates. This will enable identification of key factors influencing MPS model predictability and facilitate the development of a popPK model suitable for patients in our hospital.
免疫抑制治疗仍然是预防肾移植受者排斥反应的主要方法。虽然已经针对该人群开发了多个霉酚酸钠(MPS)的群体药代动力学(popPK)模型,但其在不同临床环境中的预测性能仍未得到验证。本研究通过外部验证系统地评估了已发表的MPS popPK模型,以评估其外推潜力。
通过对PubMed、Embase和Web of Science进行系统检索,确定已发表的肾移植受者MPS popPK模型。使用青岛大学附属医院接受MPS治疗的一组肾移植患者对这些模型进行外部评估。使用三个指标评估模型预测性能:基于模型预测的拟合优度方法、预测误差测试方法和基于模型模拟的可视化预测检查方法。
收集了我院31例患者的186个药物浓度数据,检索到4篇文献,其中1个为单室模型,3个为双室模型。在基于模型预测的拟合优度诊断和预测误差测试中,所有模型的群体预测数据均不理想,而个体预测数据显示模型1的拟合结果相对较好。基于模型模拟的可视化预测测试结果显示,模型1的拟合结果相对较好,而其余模型的观察数据与模拟数据之间的分布偏差较大,拟合效果不佳。
已发表的模型表现出显著的变异性和不令人满意的预测性能,表明治疗药物监测(TDM)仍然是MPS临床应用的一项基本要求。为了推进基于popPK的MPS个体化用药,未来的研究必须优先调查潜在的协变量。这将有助于识别影响MPS模型可预测性的关键因素,并促进开发适合我院患者的popPK模型。